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Pneumocystis carinii (PC) is a frequent cause of pneumonia in immunosup-
pressed patients, particularly those with the acquired immunodeficiency syn-
drome (AIDS) (1-3) . Very little is known about this organism because attempts
to cultivate it have been unsuccessful . With few exceptions, it has been difficult
to obtain purified and viable organisms from infected tissues (4, 5). As a result,
little is known about the biology of this organism . The development of chemo-
therapeutic agents has been guided by the presumption that the organism is a
protozoan because of its morphologic characteristics . Pentamidine isethionate,
pyrimethamine plus sulfa, trimethoprim plus dapsone, and trimethoprim plus
sulfamethoxazole have been used to treat pneumocystis pneumonia, but any of
these regimens is successful in only 50-75% ofcases, andadverse reactionsoccur
in up to 60% of patients, particularly when trimethoprim-sulfamethoxazole is
used in AIDS patients (2, 3, 6, 7) . Thus, there is a clear need for development
of more effective, less toxic antipneumocystis agents .
Although little is known regarding the metabolism of PC, both trimethoprim-
sulfamethoxazole and pyrimethamine-sulfa presumably act on pneumocystis by
the same mechanisms as they act on classic protozoa and bacteria . The diami-
nopyrimidines (trimethoprim and pyrimethamine) inhibit dihydrofolate reduc-
tase (DHFR ; EC 1 .5.1 .3), while sulfa blocks the conversion of paraaminobenzoic
acid to dihydrofolate through inhibition of the enzyme dihydropteroate synthe-
tase . Because of the classification of pneumocystis as a protozoan, it has been
assumed that the DHFR in the PC organism is similar to other protozoal and
bacterial DHFR in its sensitivity to the diaminopyrimidine inhibitors .
We have entertained the possibility that other antifolates that possess a more
classical pteridine-like structure, such as those used in cancer chemotherapy,
mightbe superior to diaminopyrimidines for the treatment ofPC . Highly charged
folate analogues such as methotrexate require a folate-specific membrane carrier
for transport (8) . Such a mechanism is present in mammalian cellsbut is generally
not found in bacteria or protozoa . Thus, antifolates that preserve the basic folate
structure have not been effective antibacterial or antiprotozoan agents because
they cannot enter these microorganisms . A newly developed reductase inhibitor,
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trimetrexate, is a quinazoline analogue of methotrexate that has the pharmaco-
logic advantage of readily penetrating cellular membranes because of its lipid
solubility (9). This report describes the kinetics of trimetrexate uptake and
DHFR binding by P. carinii, and strongly suggests that trimetrexate has substan-
tial potential as an antipneumocystis drug.
Materials and Methods
of PC DHFR.
￿
PC organisms were isolated from the homogenized lungs of
infected Sprague-Dawley rats by a two-step procedure: an initial slow-speed (260 g)
centrifugation for 5 min, which permitted removal of most of the mammalian cells,
followed by further purification by layering the supernatant onto a Ficoll-Hypaque
gradient and sedimenting at 1,000 g for 12 min. The intact PC organisms were then
harvested from the buffer/Ficoll-Hypaque interface. Organisms prepared in this manner
were found to contain only rare mammalian cells by light microscopy. PC DHFR was
prepared as a 100,000 g cytosolic preparation of sonicated (0.65 mA/s for 60 s at 4°C)
PC organisms in the presence of 50 ug/ml each of the protease inhibitors leupeptin and
chymostatin (Sigma Chemical Co., St. Louis, MO) (10). The specific activity of the PC
DHFR was found to be 3.9 -±- 1 .6 nmoles/min/mg protein at 37°C.
DHFR Catalytic Activity Assay.
￿
A spectrophotometric assay (11) was used to measure
the reaction catalyzed by either PC or rat liver DHFR (sp. act. 3.7 U/mg). Each I-ml assay
contained 0.15 umoles of NADPH (Sigma Chemical Co.) in 160 mM Tris-HCl, pH 7.2,
and 160 mM KCI with 2.3 U of DHFR and various concentrations of inhibitor. After
temperature equilibration (37°C), the reaction was initiated by the addition of 0.075
Amoles ofdihydrofolic acid (Sigma Chemical Co.), and the reaction velocity measured by
the disappearance of NADPH at 340 nm.
Relative DHFR Binding Affinity Assay.
￿
The ability of the antifolates to compete with
radiolabeled methotrexate for binding to either rat liver or PC DHFR was used as an
additional measure ofthe potency ofinteraction with the enzymefor each of the inhibitors.
The relative potency ofbinding was calculated from the ratio of the labeled methotrexate
concentration (2 x 10-9 M) to the concentration ofinhibitor required to displace one-half
of the enzyme-bound methotrexate. Each 450 Al assay contained 0.15 jAmole of NADPH,
I pmole of [sH]methotrexate (sp. act. 18 Ci/mmol; Moravek Radiochemicals, Brea, CA),
various concentrations of competitors (inhibitors), and 50 mM KH2PO4, pH 7.4. The
reaction was begun with the addition of enzyme, and after 10 min of equilibration at
21'C the unbound ligand was adsorbed using acid-washed activated charcoal, and sepa-
rated by filtration (12, 13). The protein-bound [sH]methotrexate was then counted in a
liquid scintillation counter.
Data Analysis.
￿
All values from both the catalytic and binding assays were calculated
using ALLFIT, a least-squares, curve-fitting program capable of simultaneous curve-
fitting (14) .
Drug Uptake Assay.
￿
The uptake of radiolabeled methotrexate (sp. act. 18 Ci/mmol),
trimetrexate (Drug Synthesis and Chemistry Branch, NCI, Bethesda, MD; sp. act. 13.1
mCi/mmol), and leucovorin (sp. act. 1 .5 Ci/mmol) was measured in both a human
promyelocytic cell line (HL-60) and intact PC organisms using standard techniques (9,
15). 1-5-['H]Formyltetrahydrofolic acid (leucovorin) was prepared from [3', 5', 7, 9-'H]-
folic acid (Moravek Biochemicals) by enzymatic reduction to tetrahydrofolic acid, followed
by formylation and purification (16). Intact HL-60 cells or PC organisms were suspended
in 300 Al of 160 mM Hepes/2 mM MgC12 at 21 °C and exposed to I AM concentrations
of labeled compounds for up to 30 min. After the exposures, the cells/organisms were
sedimented through 1 ml of F50 silicon fluid (General Electric, Waterford, NY) at 15,000
g for 1 min. The cell pellets were dissolved in 0.5 ml of 1 N NaOH, and radioactivity was
counted in a liquid scintillation counter. Nonspecific background counts were established
for each radiolabeled compound by adding the radiolabeled compound to the cells and
then immediately quenching the transport of the radiolabeled compound by the addition
of a 1000-fold excess of unlabeled compound.928 ALLEGRA ET AL.
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CONCENTRATION OF DHFR INHIBITOR IMI
FIGURE 1 .
￿
Inhibition curves of the reaction catalyzed by 2-3 U of PC DHFR (1 U = 1
nmole/min at 37°C) by methotrexate ([I), trimetrexate (0) pyrimethamine (O), and trimeth-
oprim (A) are illustrated as a percent of control. Assays were performed using the methods
outlined under Table I. Each point represents the mean of at least four separate experiments
with a standard error of<15%, as shown in Table I.
TABLE I
Comparative Inhibition ofDHFRfrom P. Carinii and Rat Liver by Antifolates
The tabulated íD50 values represent the concentration of each inhibitor required to inhibit the DHFR-catalyzed
reaction by 50% IDm. The binding values represent the relative ability of each inhibitor to compete with labeled
MTX for enzyme binding, and are expressed as values relative to MTX where MTX = 1 .0. All catalytic reactions
were performed with 7.5 x 10-5 M dihydro£olate as substrate, and each inhibitor was preincubated with enzyme
before initiation of the reaction to obviate potential differences in the rate of interaction of the inhibitors with the
enzyme. Each experimental point represents the mean ofat least four separate experiments.
Results and Discussion
PC organisms were harvested from the lungs ofinfected rats after 6 wk oforal
steroid therapy. The PC DHFR was isolated as acrude cytosolic preparation free
of contaminating mammalian reductase. Proof of the purity of the preparation
is dependent on several lines of evidence, including (a) the uniphasic nature of
inhibition ofthe reductase (Fig. 1); (b) inhibition constants that were significantly
different from those of rat DHFR (Sigma Chemical Co.) (Table 1); (c) lack of
detectable DHFR activity in preparations of steroid-treated rat lung exudate
lackingpneumocystis organisms but containing the same contaminatingelements,
i.e., rat lung cells, yeast, rat red cells, and rat white cells; and (d) inability to
inhibit the presumptive PC DHFR by a polyclonal antibody (a generous gift of
Dr.J. Bertino) (17) capable offully inhibiting the catalytic activity of rat DHFR.
The antifolates trimethoprim, pyrimethamine, methotrexate, and trimetrexate
were tested as inhibitors of the reaction catalyzed by the PC DHFR and by rat
liver DHFR (Fig. 1 and Table 1). Trimethoprim, the antifolate currently used to
treat PC pneumonia, was the weakest inhibitor, inhibiting the reaction by halfat
a concentration of 39,600 nM. Pyrimethamine was 10-fold more potent, but the
antineoplastic antifolates trimetrexate and methotrexate, were 1,500-fold and
Inhibitor
Rat liver
Inhibition of enzyme
activity (11350)
nM
Relative
potency of
binding
P. carinii
Inhibition of enzyme
activity (íD50)
nM
Relative
potency of
binding
Trimethoprim 390,000 t 150,000 0.0003 39,600 t 3,800 0.000011
Pyrimethamine 2,400 t 900 0.0069 2,800 t 300 0.000098
Trimetrexate 5.7 t 1 .1 0.35 26.1 f 2.2 0.17
Methotrexate 1 .4 t 0.5 1 1 .4 t 0.2 1ALLEGRA ET AL.
￿
BRIEF DEFINITIVE REPORT
￿
929
TABLE II
Steady-state Levels ofLeucovorin and Antifolates in Intact P. Carinii
andHL-60 Cells
Cells Leucovorin Trimetrexate Methotrexate
Qmoles/mg
P. carinii
￿
0
￿
76.0 ± 20.8
￿
0
HL-60
￿
16.0 ±3.5
￿
366.0 68.5
￿
10.3 ± 0.5
All experiments were performed using single-cell suspensions in transport media and
1 pM concentrations ofdrugs. Steady-state levels oftrimetrexate were reached within
2 minof exposure, while MTXand leucovorin required 30 min to reach steady-state
conditions. Each experimental point represents the mean ± SEM of at least three
separate experiments.
28,000-fold more potent than trimethoprim, respectively. Methotrexate and
trimetrexate were also more potent inhibitors of mammalian DHFR than were
the diaminopyrimidines. In contrast, bacterial DHFR was exquisitely sensitive to
the diaminopyrimidines (18).
These results were confirmed by studies ofthe ability ofthe various antifolates
to form a tight-binding complex with DHFR and NADPH, as determined by
direct measurement of the complex (Table I). Trimetrexate was found to be
almost 10,000- and 2,000-fold more potent than trimethoprim and pyrimetha-
mine, respectively, in its affinity for binding to the PC DHFR.
Classic folate structuressuch as the reduced folate leucovorin (5-formyltetrahy-
drofolic acid)and methotrexate require a specific active transport system to cross
cellular membranes (8). This system is present in mammalian cells but is lacking
in most bacteria and protozoa, and thus precludes the use of methotrexate for
the treatment of microbial infections. To determine whether the more lipid-
soluble trimetrexate would be taken up by pneumocystis, we compared the
uptake ofthis compound, the physiologic folate leucovorin, and methotrexate in
the intact PC organisms and in a human promyelocytic cell line, HL-60. Table
II illustrates that, at 1-,M concentrations of the compounds, leucovorin and
methotrexate penetrated only the mammalian cell line, while trimetrexate en-
tered both HL-60 cells and PC organisms, with steady-state amounts of 366 and
76 pmoles/mg, respectively.
These experiments demonstrate that PC DHFR is only weakly inhibited by
trimethoprim, the antifolate commonly used to treat clinical pneumocystis infec-
tion. Theclassic antifolate methotrexate and its lipid-soluble analogue trimetrex-
ate are 1500- to 28,000-fold more potent inhibitors, with ID50S of 1.4 and 26.1
nM, respectively. Transportstudies indicate that the PC organismsdo notpossess
the membrane mechanism required for the transmembrane transport of folates
(leucovorin) and methotrexate, but the hydrophobic nature of trimetrexate
allows this drug ready intracellular access. These findings suggest that a more
effective, nontoxic therapeutic approach may be to use the potent PC DHFR
inhibitor trimetrexate, with or without sulfa, simultaneously with specific rescue
of the host by leucovorin. Reduced folates such as leucovorin have well-docu-
mented ability to reverse the toxic effects of antifolate drugs on mammalian
tissues (8). The efficacy oftrimetrexate with sulfa has been compared to trimeth-
oprim with sulfa in rats that had been maintained on corticosteroids for 8 wk.930
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Groups of 30 leucovorin-treated animals were randomized to receive a 21-d
course of nothing additional, oral trimethoprim-sulfa, or oral trimetrexate-sulfa
while corticosteroids were continued. Pneumocystis scores at the end of treat-
ment (based on the percent of alveoli involved with P. carinii) (19) demonstrated
thateither treatment greatlydiminished thequantity oforganisms. Trimetrexate-
sulfa-treated rats had fewer organisms, with 23 of 30 animals having <1%
infected alveoli, while trimethoprim-sulfa-treated rats had 16 of 30 animals, and
controls only 3 of 30 animals with <1% infected alveoli (our unpublished
observations). A clinical trial is inprogresstoevaluatetheefficacyoftrimetrexate-
leucovorin with or without sulfa as an alternative to conventional therapy for
the treatment ofPC pneumonia in man (20).
Summary
The therapy of Pneumocystis carinii (PC) pneumonia is often unsuccessful,
particularly in patients with acquired immune deficiency syndrome (AIDS).
Because of difficulties in growing the organism in vitro or obtaining purified
organisms, current treatment choices have been made with little information on
the metabolic effects of therapeutic agents on PC. This report quantitates the
effects of the commonly used antifolates as well as the classic antineoplastic
antifolate methotrexate and a lipid-soluble analogue, trimetrexate, on the target
enzyme, dihydrofolate reductase (DHFR), in the PC organisms. Trimethoprim
and pyrimethamine were found to be weak inhibitors (ID5o = 39,600 and 2,800
nM, respectively), while methotrexate and trimetrexate were potent reductase
inhibitors (ID5o = 1.4 and 26.1 nM, respectively). Transport studies with radio-
labeled compounds showed that compounds with the classic folate structure
(methotrexate and leucovorin) were not taken up by the intact PC organisms. In
contrast, trimetrexate exhibited rapid uptake. These results suggest a major
therapeutic advantage may be gained by combining a potent, readily transported
PC DHFR inhibitor such as trimetrexate with the reduced folate leucovorin to
achieve a highly potent antiprotozoan effect while preventing toxicity to mam-
malian cells.
Receivedfor publication 15 September 1986 and in revisedform 26 November 1986.
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